The role of placental growth factor as a biomarker in patients with resectable gastric cancer
The association of elevated PlGF expression with disease-specific survival despite no correlation with other tumor-specific prognostic factors may indicate that PlGF could be used as an independent prognostic biomarker in gastric cancer. The ability to predict resistance to neoadjuvant treatment, as demonstrated in cell experiments, requires further investigation in a clinical setting.
Authors
- Thomas Schmidt (ORCID: https://orcid.org/0000-0002-7166-3675)
- Nerma Crnovrsanin (ORCID: https://orcid.org/0009-0006-0036-9897)
- Georg Martin Haag (ORCID: https://orcid.org/0000-0002-9410-9968)
- Henrik Nienhüser (ORCID: https://orcid.org/0000-0002-0475-9538)
- Julian Musa (ORCID: https://orcid.org/0000-0002-9138-1819)
- Timon Fiedler
- Ingmar F. Rompen (ORCID: https://orcid.org/0000-0002-0257-1654)
- Thomas Longerich (ORCID: https://orcid.org/0000-0001-8888-1030)
- Leila Sisic (ORCID: https://orcid.org/0000-0003-1260-5771)
- Sebastian Zimmer (ORCID: https://orcid.org/0000-0002-1531-2088)
- Wenjun Hu (ORCID: https://orcid.org/0000-0001-8563-8844)
- Mohammed Al‐Saeedi (ORCID: https://orcid.org/0000-0002-0583-4472)
- Daniel Nerz (ORCID: https://orcid.org/0000-0002-2587-8173)
Institutions
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- National Center for Tumor Diseases (DE)
- University Hospital Cologne (DE)
Publication Details
- Journal
- Journal of Gastrointestinal Surgery
- Published
- 2025-04-05
- DOI
- https://doi.org/10.1016/j.gassur.2025.102051
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Heidelberger Stiftung Chirurgie